SYRS

Syros Pharmaceuticals, Inc.
CAPPED RATING

Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in the understanding of the region of the genome controlling the activation and repression of genes. The companies lead candidates are SY-1425 and SY-1365.

Syros Pharmaceuticals, Inc. (SYRS) is rated D+ (1.7/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Value (C+); its weakest is Profitability (D-). The rating has held at D+ for 13 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.7 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D-
Factor Score 1.0 / 5.0
Momentum
D
Factor Score 1.2 / 5.0
Revisions
D
Factor Score 1.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -50.0%
Price Return 12M -99.5%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales N/A
ROE -386.4%

Historical Factor Score Progression

Held D+ for 13 weeks
Date Value Growth Profitability Momentum Revisions Overall
2023-12-31 C+ (2.5) C+ (2.5) D- (1.0) D (1.2) D (1.5) D+ (1.7)
2023-09-30 C+ (2.5) C- (2.0) D- (1.0) D (1.2) D (1.5) D+ (1.6)
2023-06-30 C+ (2.5) F (0.5) D+ (1.8) D (1.2) D (1.5) D (1.5)
2023-03-31 C+ (2.5) F (0.5) D+ (1.8) D (1.2) D (1.5) D (1.5)
2022-09-30 C+ (2.5) D- (0.8) D+ (1.8) D (1.2) D (1.5) D+ (1.6)
Page 1 of 3